Key facts
- Invea Therapeutics’s last known valuation is $109.7M (Mar 2026).
- It has raised $9.8M across 2 recorded rounds; the latest was Seed Round ($1.5M) in Apr 2022.
- Notable investors include Connecticut Innovations.
- Invea Therapeutics has filed 3 Form Ds with the SEC since 2022, most recently Dec 2025 ($120K sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Invea Therapeutics
Funding rounds
2 roundsAbout Invea Therapeutics
Invea Therapeutics Inc is a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or Immune-Mediated Inflammatory Diseases. Their pipeline includes INVA8001 which is designed as an oral, small molecule, highly selective and potent inhibitor of chymase, a key mediator of mast cells driving inflammation, epithelial barrier damage and fibrosis and INVA8003 is a de-novo small molecule multi-inflammasome inhibitor that has shown strong inhibition of a key pro-inflammatory marker for several IMIDs in early preclinical testing.
- Sector
- Healthcare
- HQ
- Guilford, CT, United States
- Founded
- 2021
- Employees
- 3
- Website
- inveatx.com/
- Ownership
- Privately Held (backing)
Invea Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Invea Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Invea Therapeutics in its N-PORT filings yet. We sweep new filings monthly.